StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.17−0.71 (-2.64%)

Close on Nov 18, 2026Market cap $3.34BP/E –Yield –

Viking Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Viking Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$462.63M. For fiscal 2025 it was -$278.69M. The highest annual figure on record is -$1.59M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$278.69M–
FY2024Dec 31, 2024-$87.79M–
FY2023Dec 31, 2023-$73.38M–
FY2022Dec 31, 2022-$48.40M–
FY2021Dec 31, 2021-$47.59M–
FY2020Dec 31, 2020-$21.78M–
FY2019Dec 31, 2019-$24.75M–
FY2018Dec 31, 2018-$18.76M–
FY2017Dec 31, 2017-$14.76M–
FY2016Dec 31, 2016-$11.07M–
FY2015Dec 31, 2015-$8.73M–
FY2014Dec 31, 2014-$1.59M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$138.19M–
Q2 FY2026Jun 30, 2026-$125.17M–
Q1 FY2026Mar 31, 2026-$113.98M–
Q4 FY2025Dec 31, 2025-$85.29M–
Q3 FY2025Sep 30, 2025-$94.00M–
Q2 FY2025Jun 30, 2025-$47.06M–
Q1 FY2025Mar 31, 2025-$52.33M–
Q4 FY2024Dec 31, 2024-$31.18M–
Q3 FY2024Sep 30, 2024-$21.96M–
Q2 FY2024Jun 30, 2024-$28.51M–
Q1 FY2024Mar 31, 2024-$6.13M–
Q4 FY2023Dec 31, 2023-$17.64M–
Q3 FY2023Sep 30, 2023-$19.66M–
Q2 FY2023Jun 30, 2023-$11.44M–
Q1 FY2023Mar 31, 2023-$24.64M–
Q4 FY2022Dec 31, 2022-$10.93M–
Q3 FY2022Sep 30, 2022-$13.50M–
Q2 FY2022Jun 30, 2022-$13.44M–
Q1 FY2022Mar 31, 2022-$10.53M–
Q4 FY2021Dec 31, 2021-$12.35M–
Q3 FY2021Sep 30, 2021-$10.93M–
Q2 FY2021Jun 30, 2021-$13.43M–
Q1 FY2021Mar 31, 2021-$10.88M–
Q4 FY2020Dec 31, 2020-$5.49M–
Q3 FY2020Sep 30, 2020-$5.32M–
Q2 FY2020Jun 30, 2020-$6.67M–
Q1 FY2020Mar 31, 2020-$4.30M–
Q4 FY2019Dec 31, 2019-$11.74M–
Q3 FY2019Sep 30, 2019-$3.40M–
Q2 FY2019Jun 30, 2019-$6.46M–
Q1 FY2019Mar 31, 2019-$3.15M–
Q4 FY2018Dec 31, 2018-$2.68M–
Q3 FY2018Sep 30, 2018-$5.50M–
Q2 FY2018Jun 30, 2018-$5.27M–
Q1 FY2018Mar 31, 2018-$5.30M–
Q4 FY2017Dec 31, 2017-$3.95M–
Q3 FY2017Sep 30, 2017-$3.33M–
Q2 FY2017Jun 30, 2017-$4.20M–
Q1 FY2017Mar 31, 2017-$3.28M–
Q4 FY2016Dec 31, 2016-$2.46M–

More Viking Therapeutics figures

See a number that looks wrong?